Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

Woman and Man

| Country :
| organs :
| Specialty :

Extract

The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to approximately 1 year in patients with major depressive disorder (MDD) who are partial responders to their SSRI treatment. The safety measures include the collection and reporting of discontinuation rates, treatment-emergent adverse events (TEAEs), vital signs, weight, electrocardiograms (ECGs), and laboratory analysis.

Inclusion criteria

-Major Depressive Disorder (MDD)

Kusajili – Clinical trials directory

Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake I...